SCHEMBL27174819

SCHEMBL27174819

COc1ccc(-c2ccccc2)cc1C(=O)NC(CCCNC(=N)CF)C(=O)NCc1cccc(C)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MMP2 P08253 1/20 0.43
▸ CTSL P07711 2/20 0.41
▸ CTSS P25774 2/20 0.41
▸ ATM Q13315 1/20 0.41
▸ PADI6 Q6TGC4 1/20 0.41
▸ PPARG P37231 1/20 0.41
▸ PPARA Q07869 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ NR1H4 Q96RI1 1/20 0.40
▸ KDM1A O60341 5/20 0.39
▸ CTSK P43235 1/20 0.39
▸ CTSB P07858 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ PADI4 Q9UM07 1/20 0.39
▸ PADI2 Q9Y2J8 1/20 0.39
▸ BRD4 O60885 1/20 0.38
▸ HCRTR2 O43614 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24627791 1.00 MMP2 (0.43) MMP2CTSLCTSSATMPADI6
SCHEMBL30804863 0.96 MMP2 (0.41) MMP2CTSLCTSSATMPADI6
SCHEMBL27174795 0.96 MMP2 (0.41) MMP2CTSLCTSSATMPADI6
SCHEMBL24627798 0.96 MMP2 (0.41) MMP2CTSLCTSSATMPADI6
SCHEMBL24627792 0.94 PPARA (0.46) MMP2PADI6PPARGPPARASMN1; SMN2
SCHEMBL27174804 0.94 PPARA (0.46) MMP2PADI6PPARGPPARASMN1; SMN2
SCHEMBL24627793 0.92 KDM1A (0.49) MMP2CTSLCTSSPADI6PPARG
SCHEMBL30804844 0.92 KDM1A (0.49) MMP2CTSLCTSSPADI6PPARG
SCHEMBL27174800 0.92 KDM1A (0.49) MMP2CTSLCTSSPADI6PPARG
SCHEMBL30804846 0.89 KDM1A (0.44) MMP2CTSLCTSSPADI6PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240092737-A1 SUBSTITUTED SALICYLAMIDE COMPOUNDS AND USE THEREOF HELIOS HUAMING BIOPHARMA CO., LTD. (CN) 2024-03-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240092737-A1 SUBSTITUTED SALICYLAMIDE COMPOUNDS AND USE THEREOF SYMPK, SLC10A2, SLC10A1 MMP2 1168/4885CTSL 1116/4885CTSS 1918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback